C4 Therapeutics Inc. Overview

C4 Therapeutics, Inc., a biotechnology company based in Watertown, United States, operates within the health care sector. The company is focused on developing early-stage therapies aimed at eliminating disease-causing proteins, with applications in treating cancer, neurological disorders, and other diseases. C4 Therapeutics serves its customer base primarily in Massachusetts and is listed on the Nasdaq stock exchange. More information about the company can be found on their website at www.c4therapeutics.com .

Financial Snapshot

As of May 4, 2025, C4 Therapeutics Inc. had a closing price of $1.62 per share. The company’s market capitalization stood at approximately $115.74 million. Over the past year, the stock has experienced significant volatility, with a 52-week high of $7.66 on July 15, 2024, and a 52-week low of $1.085 on April 8, 2025. The price-to-earnings (P/E) ratio was reported as -1.08, indicating that the company is not currently generating profits.

Company Focus and Strategy

C4 Therapeutics is dedicated to pioneering innovative therapies that target and neutralize proteins responsible for various diseases. Their research and development efforts are concentrated on creating treatments for cancer and neurological conditions, among others. By focusing on early-stage therapies, C4 Therapeutics aims to address unmet medical needs and improve patient outcomes.

Market Presence

The company is listed on the Nasdaq stock exchange, providing it with visibility and access to a broad investor base. Despite recent fluctuations in its stock price, C4 Therapeutics continues to pursue its mission of developing groundbreaking therapies in the health care sector.

For further details on C4 Therapeutics Inc., interested parties can visit their official website or consult financial reports and market analyses.